Australia TGA approves Specialised Therapeutics’ Niktimvo for the treatment of chronic graft-versus-host disease: Singapore Tuesday, May 5, 2026, 12:00 Hrs [IST] Independent bio ...

Joshua Sabari, MD, discusses lurbinectedin maintenance candidacy, supportive care strategies, and the critical need for ...

Every time you stand up and walk across the room, your abdominal muscles contract in a rhythm you probably never notice.

Independent biopharmaceutical company Specialised Therapeutics is pleased to announce that NIKTIMVO® (axatilimab) has been approved for use in Australia by the Therapeutic Goods Administration (TGA) ...

Could you summarize the core thesis of your research regarding the ‘Cerebral Windkessel’ and how it redefines our ...

The vast majority, 78%, of today's high school students wish they had started planning and paying for higher education ...

Metropolis Healthcare, India’s second largest and the most respected pathology laboratory chain, announced the launch of an ...

Researchers at WashU Medicine have uncovered new molecular insights into Alzheimer's disease, Parkinson's disease and other ...

The FDA has granted accelerated approval to lunsotogene parvec-cwha (Otarmeni), an adeno-associated virus (AAV) vector–based ...

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and ...

Hydrocephalus, commonly referred to as "water on the brain," is a dangerous and potentially deadly condition that can harm the brain. For more than a century, physicians have believed that the buildup ...

Phase 2 TBCRC049 trial results show tucatinib triplet therapy improves survival in HER2+ breast cancer patients with leptomeningeal metastasis. A systemic regimen consisting of tucatinib (Tukysa), ...